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**Value of the data**•The spectroscopic characterization of natural products reported in this article is important in the metabolic chemical characterization processes of plants of the same family, genus or different plant species.•It is possible the chracterization of new o related phytochemicals by comparision with the provided spectroscopic data.

1. Data {#s0005}
=======

^1^H and ^13^C Nuclear Magnetic Resonance techniques allowed the characterization of isolated compounds from the hexanic, chloroformic and methanolic extracts of *Acacia farnesiana* and esterified derivatives. NMR spectra data is shown, as well as the detailed description of the spectroscopic signals (chemical shift, integration, coupling constants, multiplicity and signal assignment), see [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}, [Fig. 10](#f0050){ref-type="fig"}, [Fig. 11](#f0055){ref-type="fig"}, [Fig. 12](#f0060){ref-type="fig"}, [Fig. 13](#f0065){ref-type="fig"}, [Fig. 14](#f0070){ref-type="fig"}, [Fig. 15](#f0075){ref-type="fig"}, [Fig. 16](#f0080){ref-type="fig"}, [Fig. 17](#f0085){ref-type="fig"}, [Fig. 18](#f0090){ref-type="fig"}, [Fig. 19](#f0095){ref-type="fig"}, [Fig. 20](#f0100){ref-type="fig"}, [Fig. 21](#f0105){ref-type="fig"}, [Fig. 22](#f0110){ref-type="fig"} with this article.Fig. 122E-stimasta-5,22-dien-3β-ol, NMR ^1^H (400 MHz CDCl~3~) δ ppm: 0.69 (s, 3H, Me-18), 0.79 (d, *J*=6.92 Hz, 3H, Me-27), 0.80 (t, *J*=7.1 Hz, 3H, Me-29), 0.83 (d, *J*=7.32 Hz, 3H, Me-26), 0.86 (d, *J*=3.8 Hz, 2H, H-28), 0.92 (d, *J*=6.4 Hz, 2H, H-9, H-24), 1.01 (s, 3H, Me-19), 1.02 (d, *J*=7. 72 Hz, 3H, Me-21), 1.10 (m, 1H, H-14), 1.04 (m, 2H, H-1), 1.07 (m, 2H, H-15), 1.11 (m, 1H, H-14), 1.13 (m, 1H, H-17), 1.16 (m, 1H, H-12), 1.28 (m, 1H, H-16), 1.41 (m, 1H, H-20), 1.53 (m, 2H, H-7), 1.54 (m, 1H, H-11), 1.83 (m, 1H, H-25), 1.84 (m, 2H, H-2), 1.85 (m, 1H, H-16), 1.99 (m, 1H, H-8), 2.0 (m, 2H, H-12), 2.28 (m, 2H, H-4), 3.52 (m, 1H, H-3), 5.01 (dd, *J*=15.1, 8.6 Hz, 1H, H-23), 5.15 (dd, *J*=15.1, 8.5 Hz, 1H, H-22), 5.35 (brd, *J*=4.72 Hz, 1H, H-6).Fig. 1Fig. 222E-stimasta-5,22-dien-3β-ol, NMR ^13^C (100 MHz, CDCl~3~) δ ppm: 12.05 (C18), 12.25 (C29), 19.03 (C27), 19.40 (C19), 21.08 (C11, C26), 21.21 (C21), 24.36 (C15), 25.41 (C28), 28.92 (C16), 31.67 (C2), 31.88 (C7, C8), 31.90 (C25), 36.51 (C10), 37.26 (C1), 39.78 (C12), 40.49 (C20), 42.22 (C13), 42.31 (C4), 50.14 (C9), 51.24 (C24), 55.96 (C17), 56.87 (C14), 71.81 (C3), 121.71 (C6), 129.28 (C23), 138.32 (C22), 140.76 (C5).Fig. 2Fig. 322E-stimasta-5,22-dien-3β-acetyl, NMR ^1^H (400 MHz, CDCl~3~) δ ppm: 0.69 (s, 3H, Me-18), 0.79 (d, *J*=6.96 Hz, 3H, Me-27) 0.80 (t, *J*=7.04 Hz, 3H, Me-29), 0.82 (d, *J*=1.74 Hz, 2H, H-28), 0.83 (d, *J*=7.2 Hz, 3H, Me-26),), 0.91 (m, 1H, H-24) 0.92 (d, *J*=6.54 Hz, 1H, H-9), 1.02 (s, 3H, Me-19), 1.021 (d, *J*=6.36 Hz, 3H, Me-21), 1.12 (m, 1H, H-14), 1.13 (m, 2H, H-15), 1.16 (m, 2H, H-1), 1.17 (m, 1H, H-17), 1.18 (m, 1H, H-12), 1.28 (m, 1H, H-16), 1.42 (m, 1H, H-20), 1.53 (m, 2H, H-11), 1.54 (m, 2H, H-7), 1.83 (m, 1H, H-25), 1.84 (m, 2H, H-2), 1.87 (m, 1H, H-16), 1.98 (m, 1H, H-8), 1.99 (m, 2H, H-12), 2.03 (s, 3H, CH~3~CO), 2.32 (m, 2H, H-4), 4.6 (m, 1H, H-3), 5.01 (dd, *J*=15.16, 8.64 Hz, 1H, H-23), 5.15 (dd, *J*=15.16, 8.6 Hz, 1H, H-22), 5.37 (brd, *J*=4.64, 1H, H-6).Fig. 3Fig. 422E-stimasta-5,22-dien-3β-acetyl. NMR ^13^C (100 MHz, CDCl~3~) δ ppm: 12.04 (C18), 12.24(C29), 18.98 (C27), 19.30 (C19), 21.01 (C11), 21.08 (C26), 21.21 (C21), 21.44 (CH~3~CO), 24.35 (C15), 25.40 (C28), 27.77 (C2), 28.90 (C16), 31.86 (C7, C8), 31.88 (C25), 36.59 (C10), 36.99 (C1), 38.12 (C4), 39.62 (C12), 40.49 (C20), 42.20 (C13), 50.05 (C9), 51.23 (C24), 55.93 (C17), 56.78 (C14), 74.0 (C3), 122.63 (C6), 129.28 (C23), 138.31 (C22), 139.65 (C5), 170.56 (CH~3~CO).Fig. 4Fig. 5Tetracosanoic acid (2S)-2, 3-dihydroxypropyl ester, NMR ^1^H (400 MHz, CDCl~3~) δ ppm: 0.88 (t, J=6.78 Hz, 3H, Me-24), 1.25 (sa, 38H, (CH~2~)~19~, C4-C22), 1.50 (sa, 1H, OH-3´), 1.63 (m, 4H, H-3, H-23), 2.04 (s, 1H, OH-2´), 2.35 (t, *J*=7.58 Hz, 2H, H-2), 3.60 (dd, *J*=11.46, 5.78 Hz, 1H, H-3´β), 3.70 (dd, *J*=11.46, 3.98 Hz, 1H, H-3´α), 3.94 (m, 1H, H-2´), 4.15 (dd, *J*=11.68, 6.12 Hz, 1H, H-1´β), 4.21 (dd, *J*=11.64, 4.6 Hz, 1H, H-1´α).Fig. 5Fig. 6Tetracosanoic acid (2*S*)-2, 3-dihydroxypropyl ester, NMR ^13^C (100 MHz, CDCl~3~) δ ppm: 14.35 (C24), 22.91 (C23), 25.13 (C3), 29.34 (C4), 29.46 (C5), 29.58 (C8), 29.67 (C9), 29.82 (C21), 29.86 (C6), 29.88 (C7), 29.92 (C10-C20), 32.14 (C22), 34.37 (C2), 63.53 (C3´), 65.38 (C1´), 70.48 (C2´), 174.61 (C1).Fig. 6Fig. 7Stigmasta-5,22-dien-3β-O-D-glucopyranoside, NMR ^1^H (400 MHz, DMSO-d~6~) δ ppm: 0.64 (s, 3H, Me-18), 0.79 (t, *J=* 7.40 Hz, 3H, Me-29), 0.80 (d, *J=* 7.64 Hz, 3H, Me-27), 0.81 (m, 1H, H-9), 0.83 (m, 1H, H-24), 0.89 (d, *J=* 6.24 Hz, 3H, Me-26), 0.95 (s, 3H, Me-19), 0.99 (d, *J=* 6.36 Hz, 3H, Me-21), 1.03 (m, 1H, H-17), 1.07 (m, 2H, H-15), 1.09 (m, 1H, H-9), 1.14 (m, 2H, H-12), 1.19 (d, *J*= 7.1 Hz, 1H, H-4), 1.22 (m, 2H, H-11), 1.37 (m, 2H, H-2), 1.40 (m, 1H, H-20), 1.46 (m, 1H, H-25), 1.49 (m, 2H, H-7), 1.62 (dd, *J=* 6.4, 11.6, 1H, H-8), 1.78 (m, 1H, H-16), 1.80 (m, 1H, H-4), 1.93 (m, 1H, H-16), 2.11 (m, 1H, H-1), 2.36 (dd, *J=* 3.0, 13.3 Hz, 1H, H-1), 2.88 (m, 1H, H-2´), 3.01 (m, 2H, H-5´), 3.04 (m, 2H, 4´), 3.11 (m, 1H, H-3´), 3.46 (m, 1H, H-3), 3.48 (m, 1H, H-6´a), 3.63 (dd, *J=* 10.7, 5.4 Hz, 1H, H-6´b), 4.21 (d, *J=* 7.72 Hz, 1H, H-1´), 4.45 (t, *J=* 5.6 Hz, 1H, OH-6´), 4.88 (sa, 1H, OH-4´), 4.89 (sa, 1H, OH-2´), 4.91 (d, *J* = 4.5 Hz, 1H, OH-3´), 5.01 (dd, *J=* 15, 8.72, Hz, 1H, H-23), 5.15 (dd, *J=* 15.04, 8.62 Hz, 1H, H-22), 5.32 (sa, 1H, H-6).Fig. 7Fig. 8Stigmasta-5,22-dien-3β-O-D-glucopyranoside. NMR ^13^C (100 MHz, DMSO-d~6~): δ (ppm): 11.69 (C29), 11.80 (C18), 18.63 (C21), 18.85 (C27), 18.95 (C19), 19.12 (C26), 22.62 (C11), 23.88 (C28), 24.88 (C15), 29.26 (C16), 31.38 (C7, C8), 31.43 (C24, C25), 33.35 (C2), 35.49 (C20), 36.23 (C10), 36.83 (C4), 38.30 (C1), 39 (C12), 41.87 (C13), 49.61 (C9), 55.43 (C17), 56.27 (C14), 61.11 (C6´), 70.12 (C2´), 73.48 (C4´), 76.76 (C5´), 76.92 (C3´), 76.98 (C3), 100.78 (C1´), 121.24 (C6), 130.74 (C23), 138.06 (C22), 140.47 (C5).Fig. 8Fig. 9Stigmasta-5,22-dien-3β-O-D-tetraacetylglucopyranoside, NMR ^1^H (400 MHz, CDCl~3~) δ ppm: 0.67 (s, 3H, Me-18), 0.80 (t, *J=*7.24 Hz, 3H, Me-29), 0.83 (d, *J=*7.04 Hz, 3H, Me-27), 0.91 (d, *J=*6.44 Hz, 3H, Me-26), 0.98 (s, 3H, Me-19), 1.02 (d, *J=*6.64 Hz, 3H, Me-21), 2.00 (s, 3H, [CH]{.ul}~[3]{.ul}~CO-3´), 2.02 (s, 3H, [CH]{.ul}~[3]{.ul}~CO-2´), 2.05 (s, 3H, [CH]{.ul}~[3]{.ul}~CO-4´), 2.08 (s, 3H, [CH]{.ul}~[3]{.ul}~CO-6´), 3.48 (m, 1H, H-3), 3.67 (m, 1H, H-2´), 4.1 (dd, *J=*12.2, 2.88 Hz, 1H, H-6´a), 4.26 (dd, *J=*12.22, 4.82 Hz, 1H, H-6´b), 4.59 (d, *J=*8.0 Hz, 1H, H-1´), 4.96 (t, *J=* 9.48 Hz, 1H, H-3´), 5.03 (dd, *J=* 14.16, 5.56 Hz, 1H, H-23), 5.07 (t, *J=* 9.68 Hz, 1H, H-5´), 5.13 (dd, *J=*15.16, 6.52 Hz, 1H, H-22), 5.20 (t, *J=*9.52 Hz, 1H, H-4´) 5.36 (da, *J=*4.84 Hz, 1H, H-6).Fig. 9Fig. 10Stigmasta-5,22-dien-3β-O-D-tetraacetylglucopyranoside. NMR ^13^C (100 MHz, CDCl~3~) δ ppm: 11.89(C29), 12.02 (C18),18.81 (C21),19.07(C27), 19.39 (C19), 19.85 (C26), 20.65 ([CH]{.ul}~[3]{.ul}~CO-6´), 20.68 ([CH]{.ul}~[3]{.ul}~CO-4´), 20.76 ([CH]{.ul}~[3]{.ul}~CO-3´), 20.80 ([CH]{.ul}~[3]{.ul}~CO-2´), 21.08 (C11), 23.10 (C28), 24.33 (C15), 28.27 (C16), 29.48 (C24), 31.90 (C8, C25), 31.98 (C7), 33.98 (C-2), 36.16 (C20), 36.76 (C10), 37.23 (C1), 38.95 (C4), 39.77 (C12), 42.36 ( C13), 50.20 (C9), 56.09 (C17), 56.79 (C14), 62.15 (C6´), 68.53 (C4´), 71.54 (C3´), 71.73 (C5´), 72.96 (C3), 80.12 (C2´), 99.68 (C1´), 122.20 (C6), 129.34 (C23), 138.32 (C22), 140.40 (C5), 169.34 (CH~3~[CO]{.ul}-3´), 169.44 (CH~3~[CO]{.ul}-4´), 170.40 (CH~3~[CO]{.ul}-2´), 170.74 (CH~3~[CO]{.ul}-6´).Fig. 10Fig. 11Methyl gallate, NMR ^1^H (400 MHz, Acetone-d~6~) δ ppm: 3.78 (s, 3H, OMe), 7.11 (s, 2H, H-2, H-6), 8.17 (s, 3H, OH).Fig. 11Fig. 12Methyl gallate, NMR ^13^C (100 MHz, Acetone-d~6~) δ ppm: 51.01 (OMe), 108.92 (C2, C6), 120.93 (C1), 137.82 (C4), 145.16 (C3, C5), 166.27 ([CO]{.ul}OR).Fig. 12Fig. 13Methyl 3,4,5-triacetyloxybenzoate, NMR ^1^H (400 MHz, CDCl~3~) δ ppm: 2.32 (s, 9H, 3x [CH]{.ul}~[3]{.ul}~CO), 3.92 (s, 3H, OMe), 7.82 (s, H-2, H 6).Fig. 13Fig. 14Methyl 3,4,5-triacetyloxybenzoate, NMR ^13^C (100 MHz, CDCl~3~) δ ppm: 20.17 ([CH]{.ul}~[3]{.ul}~CO-4), 20.58 ([CH]{.ul}~[3]{.ul}~CO-3, [CH]{.ul}~[3]{.ul}~CO-5), 52.57 (OCH~3~), 122.22 (C2, C6), 128.29 (C1), 138.58 (C4), 143.39 (C3, C5), 164.90 (CH~3~[CO]{.ul}-1), 166.44 (CH~3~[CO]{.ul}-4), 167.61 (CH~3~[CO]{.ul}-3, CH~3~[CO]{.ul}-5).Fig. 14Fig. 15Gallic acid, NMR ^1^H (400 MHz, Acetone-d~6~) δ ppm: 3.08 (sa, 4H, OH-4), 7.14 (s, 2H, H-2, H-6), 8.22 (sa, 2H, OH-3, OH-5).Fig. 15Fig. 16Gallic acid, NMR ^13^C (100 MHz, Acetone-d~6~) δ ppm: 109.22 (C2, C6), 121.15 (C1), 137.77 (C4), 145.11 (C3, C5), 166.82 (COOH).Fig. 16Fig. 17(2S) -Naringenin 7-O-β-D-glucopyranoside, NMR ^1^H (400 MHz, DMSO-d~6~) δ ppm: 2.73 (dd, *J=* 17.1, 2.62 Hz, 1H, H-3β), 3.14 (m, 1H, H-3α), 3.22 (m, 2H, H-4´´, H-2´´), 3.37 (m, 2H, H-3´´, H-5´´), 3.42 (dd, *J=* 11.68, 5.64 Hz, 1H, H-6a´´), 3.65 (dd, *J=* 11.04, 4.68 Hz, 1H, H-6b´´), 4.54 (t, *J=* 5.56, 1H, OH-6"), 4.95 (d, *J=* 7.4 Hz, 1H, H-1´´), 5.01 (d, *J=* 5.2 Hz, 1H, OH-4´´), 5.08 (d, *J=* 4.72 Hz, 1H, OH-3´´), 5.33 (d, *J=* 4.88 Hz, 1H, OH-2´´), 5.50 (dd, *J=* 12.6, 2.48 Hz, 1H, H-2), 6.13 (d, *J=* 2.2, 1H, H-6), 6.15 (d, *J=* 1.96, 1H, H-8), 6.79 (d, *J=* 8.4 Hz, 2H, H-3´, H-5´), 7.32 (d, *J=* 8.44 Hz, 2H, H-2´, H-6´), 9.59 (s, 1H, OH-4´), 12.05 (s, 1H, OH-5).Fig. 17Fig. 18(2S) -Naringenin 7-O-β-D-glucopyranoside. NMR ^13^C (100 MHz, DMSO-d~6~) δ ppm: 42.55 (C3), 61.05 (C6´´), 69.98 (C4´´), 73.50 (C2´´), 76.80 (C3´´), 77.56 (C5´´), 79.13 (C2), 95.92 (C8), 96.97 (C6), 100.10 (C1´´), 103.73 (C10), 115.65 (C3´, C5´), 128.89 (C2´, C6´), 129.11 (C1´), 158.28 (C4´), 163.25 (C5), 163.41 (C9), 165.79 (C7), 197. 67 (C4).Fig. 18Fig. 19Pinitol, NMR ^1^H (400 MHz, D~2~O) δ (ppm): 3.18 (t, *J=*9.64 Hz, 1H, H-6), 3.44 (s, 3H, OCH~3~), 3.49 (t, *J=*9.64 Hz, 1H, H-1), 3.55 (dd, *J=*9.94, 2.38 Hz, 1H, H-2), 3.65 (dd, *J=*9.98, 2.42 Hz, 1H, H-5), 3.84 (m, 2H, H-3, H-4).Fig. 19Fig. 20Pinitol. NMR ^13^C (100 MHz, D~2~O) δ (ppm): 59.67 (OCH~3~), 69.76 (C5), 70.47 (C2), 71.40 (C3), 71.61 (C4), 72.07 (C1), 82.72 (C6).Fig. 20Fig. 21Sucrose, NMR ^1^H (400 MHz, D~2~O) δ (ppm): 3.43 (t, *J=*9.42 Hz, 1H, H-4), 3.52 (dd, *J=*10, 3.84 Hz, 1H, H-2), 3.63 (s, 2H, H-1´), 3.72 (t, *J=*9.56 Hz, 1H, H-3), 3.78 (d, *J=*2.96 Hz, 2H, H-6), 3.79 (d, *J=*2.8 Hz, 2H, H-6´), 3.83 (m, 1H, H-5), 3.86 (m, 1H, H-5´), 4.01 (t, *J=* 8.56 Hz, 1H, H-4´), 4.18 (d, *J=*8.76 Hz, 1H, H-3´), 5.38 (d, *J=*3.88 Hz, 1H, H-1).Fig. 21Fig. 22Sucrose. NMR ^13^C (100 MHz, D~2~O) δ (ppm): 62.59 (C6), 63.82 (C1´), 64.84 (C6´), 71.70 (C4), 73.55 (C2), 74.88 (C5), 75.05 (C3), 76.47 (C4´), 78.88 (C3´), 83.85 (C5´), 94.66 (C1), 106.17 (C2´).Fig. 22

2. Experimental design, materials and methods {#s0010}
=============================================

One-dimensional nuclear magnetic resonance (NMR) spectra were obtained using the Bruker AVANCE III HD 400 MHz equipment. Deuterated solvents (CDCl~3~, DMSO-d~6~, acetone-d~6~ and D~2~O) were used based on the dissolution needs of the compounds to be studied and tetramethylsilane (TMS) as internal standard.

5--10 mg of each compound analyzed was weighed in analytical balance and 0.5 mL of deuterated solvent was added to sample until complete solubility. Then solution was placed in a clean and dry resonance tube.

To obtain the spectroscopic data of hydrogen nucleus (^1^H), a 400 MHz equipment frequency was used, while for the carbon nucleus (^13^C) a frequency of 100 MHz was used.
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